Citius Oncology Inc (CTOR) Cotización

Standard Fibonacci pullback,pattern continues up from here.

Gap filled and hit the bottom bolie(5day),higher high should start the chase up!

Today news,https://stocks.apple.com/Ab9gzALbjS4ilQFYvXP1zNQ

Just for your info. Forgot to attach in previous response.

Here is the link to the official fililing to the SEC filed on 12/27/2024 see page f4 for the income statement.

https://www.otcmarkets.com/filing/html?id=18074417&guid=IX0-keY-Hd5eJth

Personally i do not pay attention to charts.

Charts do not take into financial status,or any potential cataylts,earnins etc.The chart is solely based on programming and is based on current market conditions and changes as the the price goes up or down only.

They are strickly for trading.

I am a long term investor, and invest based on the the potential of the product, which i believe will be big.

But that is just me.

Thanks!,chart is bullish breakout,potential is astronomical,I bought the chart

It is incorrect.

They have no earnings. Always look at the financials. Schwab also say there are no financials. Svhwab does not have any but there are.

I posted a link to the financials.

My platform Charles Schwab info

????

Are you sure.

They have a loss of (-.31)

and a p/e of ( -4.4839)

https://www.otcmarkets.com/stock/CTOR/financials

What ever your looking at is incorrect.

They have no revenues and just went public as a spin off in 8/24, they do not have any earnings.

Price/earnings $5.37,earnings.24 per share,extremely undervalued

Buyout,merger,drug purchase from big pharma,something big coming when Jeffries is involved,this will get found!

Seriously, we went through that before.

I sent to you on another board:
CTOR isn't only a few million market cap.

The market cap is appox 105 million @$1.45

CTOR has 71,552,402 shares O/S a/0 9/30/2024, wheseas CTXR owns 92.2%.

See outstanding shares here (and on their Financials that were filed last week)

https://www.otcmarkets.com/stock/CTOR/security



https://www.otcmarkets.com/filing/html?id=18074417&guid=Q90-kqGyIgvnJth

Float is appox. 5.9 million.

$CTOR BULLISH ✨💎✨💎✨💎✨ Tomorrow breakout $2.00

(LYMPHIR) is set to begin selling this quarter – exciting times ahead! It's hard to believe that a Phase 3 FDA-approved stock with a market cap of only a few million dollars even exists. This situation is almost unbelievable.

This stock is set for a massive move. It's the best bargain and super undervalued. There is no offering, no dilute, and a 5.9 million share float. The chart looks poised for a breakout $2.00. This will fly soon! It’s a matter of time, Bullish.

Lymphir is the only CTCL therapy that targets the interleukin-2 (IL-2) receptor found on malignant T-cells and Tregs. This is the first indication for Lymphir and Citius Pharma’s first FDA-approved product.

Citius Pharmaceuticals (CTXR), the parent company, owns 92% of the outstanding shares of CTOR, and it also owns Mino-Lok.

Mino-Lok (For Cancer and Infection Prevention)
Successful Phase 3 Clinical Trial of Mino-Lok®. Mino-Lok® is on a pathway to a New Drug Application (NDA) submission

This is a high volume (279,379) for CTOR for the first hour of trading considering they have approx. 5.9 million share float.

This is 4.7% of the float with 5 1/2 hours of trading to go today.

Citius Oncology Engages Jefferies as Exclusive Financial Advisor to Explore Strategic Alternatives

January 06 2025 - 7:50AM
PR Newswire (US)

CRANFORD, N.J., Jan. 6, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or "the Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has retained Jefferies LLC as its exclusive financial advisor to assist in evaluating strategic alternatives aimed at maximizing shareholder value.

The engagement of Jefferies underscores Citius Oncology's commitment to exploring all avenues for enhancing its strategic positioning and advancing its mission to improve patient outcomes in oncology. Strategic alternatives under consideration may include, but are not limited to, partnerships, joint ventures, mergers, acquisitions, licensing or other strategic transactions.

"We are excited to partner with Jefferies, a leading global investment bank with deep expertise in the life sciences sector, to help us explore opportunities that align with our long-term vision. As we prepare to launch our first cancer therapy, now is an opportune time to review options that would be in the best interests of patients and shareholders," said Leonard Mazur, Chief Executive Officer of Citius Oncology. "Our goal is to deliver value to shareholders by making a meaningful impact in the oncology space."

Citius Oncology is committed to commercializing LYMPHIR™, recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic therapy.

The Company has not set a specific timeline for the strategic engagement and does not intend to disclose developments unless and until its Board of Directors has approved a specific transaction or course of action, or the company otherwise determines that disclosure is appropriate or necessary. There can be no assurance, however, that this process will result in a strategic transaction or other alternative.

About LYMPHIR™ (denileukin diftitox-cxdl)

LYMPHIR is a targeted immune therapy for relapsed or refractory CTCL indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the DT fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death. Denileukin diftitox-cxdl demonstrated the ability to deplete immunosuppressive regulatory T lymphocytes (Tregs) and antitumor activity through a direct cytocidal action on IL-2R-expressing tumors.

In 2021, denileukin diftitox received regulatory approval in Japan for the treatment of CTCL and PTCL. Subsequently, in 2021, Citius acquired an exclusive license with rights to develop and commercialize LYMPHIR in all markets except for Japan and certain parts of Asia. LYMPHIR was approved by the FDA in August 2024.

About Citius Oncology, Inc.

Citius Oncology, Inc. (Nasdaq: CTOR) is a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds $400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology's competitive positioning. For more information, please visit www.citiusonc.com.

About Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. In August 2024, the FDA approved LYMPHIR, a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Citius Pharma's late-stage pipeline also includes Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 Trial. Citius is actively engaged with the FDA to outline next steps for both programs. Citius Pharmaceuticals owns 92% of Citius Oncology. For more information, please visit www.citiuspharma.com.

https://ih.advfn.com/stock-market/NASDAQ/citius-oncology-CTOR/stock-news/95198794/citius-oncology-engages-jefferies-as-exclusive-fin

$CTOR

ctor.......................................https://stockcharts.com/h-sc/ui?s=ctor&p=W&b=5&g=0&id=p86431144783

No problem.

Happens to everyone.

I don't know why OTCM shows the wrong o/s it's my mistake not to dig into the DD

Just my opinion:

It will be a banner year for CTOR, with the expected 1st sales in the 1st QTR. 2025 for :

LYMPHIR™ (denileukin diftitox-cxdl) Injection 300 mcg.

NOW FDA APPROVED

LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

CTOR: Thanks for the heads-up!!

Loaded up 1.07 -1.08

The real money for CTOR is in CTO (Captor Therapeutics) stock indeed lie in the patent-pending combination of IL-2 with checkpoint inhibitors, particularly in the context of making cold tumors more responsive to immunotherapy. If this combination proves effective in clinical trials, it could become a breakthrough in cancer immunotherapy, positioning the company well for long-term success in the oncology market. Here is why.

1. IL-2 and Tumor Microenvironment:
Interleukin-2 (IL-2) is a cytokine that plays a pivotal role in regulating immune responses. In cancer therapy, IL-2 has been shown to have the potential to stimulate the immune system, particularly T-cells and natural killer (NK) cells, enhancing their ability to target and destroy tumor cells. This action can help "convert cold tumors into hot tumors", meaning tumors that are generally resistant to immune system attack (cold tumors) may become more susceptible to immune intervention (hot tumors).
after IL-2 treatment. This shift is crucial because the immune system often struggles to recognize and attack cold tumors due to immune suppression or a lack of immune activity in the tumor microenvironment.

2. Combination with Checkpoint Inhibitors:
The idea of combining IL-2 with checkpoint inhibitors—such as PD-1 or CTLA-4 inhibitors—is particularly intriguing. Checkpoint inhibitors work by blocking the pathways that tumors use to evade the immune system, essentially "releasing the brakes" on immune activity. However, even with checkpoint inhibition, the immune system may still struggle to effectively target some tumors.
Adding IL-2 could potentially boost the immune system's response, making the checkpoint inhibitors more effective by increasing the number of active immune cells at the tumor site.

3. Captor Therapeutics' Approach:
If Captor Therapeutics is working on a combination therapy that leverages these two mechanisms—IL-2 and checkpoint inhibitors—it could offer a unique approach to enhancing the anti-tumor immune response. The combination could be particularly effective for tumors that are traditionally hard to treat, such as cold tumors that lack sufficient immune cell infiltration.

By addressing both the immune system's activation and the tumor's ability to suppress immune cells, the therapy could have synergistic effects, potentially providing better outcomes than either approach alone.

4. Patent Potential:
With the potential to combine IL-2 with checkpoint inhibitors in a novel way, this could be a major asset for Captor Therapeutics (or any company in a similar position). If they hold intellectual property around this combination, it could offer significant competitive advantage, making their therapy highly valuable. The combination of immune-stimulating IL-2 with immune checkpoint inhibitors could represent a next-generation immuno-oncology treatment, leading to high market demand if clinical trials show promising results.

Yes i know.

CTOR now has the product and is expected to have sales of the product in the first quarter of 2025

i posted that on another investment sight, under a diffrent screen name.

Super tiny float! O/S at 100 million, insiders hold 95.88%, leaving just 4.12 million shares available on the market. Institutions own 17.08% (703,696 shares), which means the float is only 3,146,304 shares. That's incredibly low! No dilution and a super tight float.

Major Holders Breakdown
95.88% % of Shares Held by All Insider
0.70% % of Shares Held by Institutions
17.08% % of Float Held by Institutions
12 Number of Institutions Holding Shares

The value should be focusing on $CTOR because now Citius Oncology, Inc. owned LYMPHIR - under page 1
All closing conditions as referenced in the Merger Agreement have either been met or waived by the parties. Certain closing conditions that were waived by the parties, pursuant to the Merger Agreement, include, but are not limited to: (i) Section 7.18(a) and 7.18(b), which (a) required Citius Pharma to transfer the LYMPHIRTM (denileukin diftitox) trademark to the Company prior to Close and (b) required Citius Pharma to send a letter notifying the FDA that all ownership rights of the BLA and IND will transfer from the Citius Pharma to the Company within five business days of Citius Pharma’s receipt of the Notice of Approval for LYMPHIR from the U.S. Food & Drug Administration, which transfers will instead occur within 60 days following the Closing,

https://www.otcmarkets.com/filing/html?id=17769535&guid=w6O-kFUFOe-FJth

CTOR..................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

Got in on the dip. $$CTOR$$

CTOR: (See 'CHART, below!!) Everyone's watchin' to see what YOU will do, my lovely CTOR SHARES!!!!

CTOR: I dumped all of the other CRAP I had grabbed today, & then RUSHED over here to get a piece of THIS ONE!! (See ME below, right now --- I am exhausted!!!)

CTOR is up 85% with very heavy volume, and so far there is no indication why!

There is always a reason though.

CTOR.........................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

Extremely strong this morning .

CTOR is up 61.76% @ 5:21am with heavy volume trading @$1.65.

As of now no news as to what is the catalyst for the rise and interest.

CTOR...................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

Thanks it's a runner $1.40 +'35%

The catheter is in CTXR.

CTOR'S produduct is LYMPHIR


On August 7, 2024, the FDA issued a biologics license to market LYMPHIR for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy.


CTOR plans to commercialize LYMPHIR in 1/25.

Completed a few months back Phase 3 catheter $1.06 +'15% 

CTOR has been up 40.2% since OCT.9.2024.

CTOR.....................................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

UNRELENTING DUMPING!!!

oops, I missed that, thanks!

That filing had to do with the Units, Rights for CTOR not the common.

Look for this in the filing
Unit, Right
(Description of class of securities) . Link below:

https://www.otcmarkets.com/filing/html?id=17756195&guid=ThL-kFzAdOZnJth

CTOR filed a form 25 in August. Why does it still look like CTOR is listed on NASDAQ?

INHOSPITABLE SELLING

UNADULTERATED DUMPING

CTOR..........................https://stockcharts.com/h-sc/ui?s=CTOR&p=W&b=5&g=0&id=p86431144783

UNMITIGATED DUMPING

CEASELESS SELLING

CTOR under $2

IMMEASURABLE DUMPING

a NEW ALL-TIME LOW